Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs

Arcturus Therapeutics is doubling down on mRNA technology. The biotech said Monday that it's prioritizing its experimental mRNA drugs, with a focus on programs for cystic fibrosis and a rare disease ...